Overview

Immuno-oncology is aimed at destroying cancer cells by stimulating the patient's immune system without affecting healthy tissues, with the goal of delivering long-lasting responses and cure. This process is tightly regulated by interactions between receptors on immune cells that influence the immune response against cancer cells. 
 
LeadArtis has generated an array of novel drug candidates, including a tumor-targeted costimulatory MT simultaneously targeting a clinically validated tumor-associated antigen (TAA) on cancer cells and T cell costimulatory Tumor Necrosis Factor Receptors (TNFR). A follow-up candidate is a T cell-recruiting bispecific antibody with the ATTACK configuration. 
 
These Trimerbodies allow us to fine tune the potency of the T cell activation and cell killing, potentially improving the tolerability of tumor immunotherapy. We have demonstrated highly effective and well-tolerated killing of target cells in a variety of assays.

Latest News

Leadartis announces the publication "An Fc-free EGFR-specific 4-1BB-agonistic trimerbody displays broad anti-tumor activity in humanized murine cancer models without toxicity” in Clinical Cancer Research
02-04-2021
Leadartis reaches a major milestone with the demonstration of absence of toxicity of its drug candidate in preclinical models
13-01-2021

Leadartis reaches a major milestone with the demonstration of...

Leadartis featured in EXPANSION as a ‘Start up’ that leads the fight against cancer
10-11-2020

...